CureDuchenne’s success in venture philanthropy has attracted the attention of the medical research community around the world. Last week, CureDuchenne CEO Debra Miller and Vice President of CureDuchenne Medical and […]
A new study from The Ottawa Hospital and the University of Ottawa is poised to completely change our understanding of Duchenne muscular dystrophy and pave the way for far more effective treatments.
Santhera Pharmaceuticals (SIX: SANN) announces that it has now completed comparative analyses of the respiratory outcomes for patients in its successful Phase III DELOS trial with data from a natural history DMD patient cohort collected by the Cooperative International Neuromuscular Research Group (CINRG).
Did you know that heart failure is very common and often fatal in patients with Duchenne muscular dystrophy? The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a clinical trial […]
Moving someone who has Duchenne from one location to another is no easy task, especially when considering patient and caregiver safety. Jennifer Wallace is a physical therapist who specializes in […]
Capricor Therapeutics and CureDuchenne hosted a webinar on November 3, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Adminstration has cleared Capricor’s Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy. The webinar provided an overview of the clinical trial which is being conducted at several sites in the U.S.
Duchenne muscular dystrophy is a debilitating genetic disorder that has garnered much attention lately as the U.S. Food and Drug Administration prepares to review two experimental drugs that could soon treat some patients with the degenerative muscle disease.
A team of researchers at the University of Michigan Health System identified a novel method of triggering the “instructions” normally given to cells by the muscle protein dystrophin, which is found in cardiac muscles cells and in muscles used for movement. This new method could produce a key to a breakthrough therapeutic strategy for patients with Duchenne Bekcer muscular dystrophy.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that the European Commission (EC) has granted
orphan medicinal product designation to CAT-1004 for the
treatment of Duchenne muscular dystrophy (DMD).
